Nyrada (NYR) Stock Overview
A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NYR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nyrada Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.24 |
| 52 Week High | AU$0.27 |
| 52 Week Low | AU$0.032 |
| Beta | 0.82 |
| 1 Month Change | 133.33% |
| 3 Month Change | 133.33% |
| 1 Year Change | 276.92% |
| 3 Year Change | 48.48% |
| 5 Year Change | 48.48% |
| Change since IPO | 2.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| NYR | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 40.0% | -6.9% | -0.5% |
| 1Y | 276.9% | -32.9% | 8.4% |
Return vs Industry: NYR exceeded the Australian Pharmaceuticals industry which returned -32.9% over the past year.
Return vs Market: NYR exceeded the Australian Market which returned 8.4% over the past year.
Price Volatility
| NYR volatility | |
|---|---|
| NYR Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 11.7% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.8% |
Stable Share Price: NYR's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: NYR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | James Bonnar | www.nyrada.com |
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Nyrada Inc. Fundamentals Summary
| NYR fundamental statistics | |
|---|---|
| Market cap | AU$54.84m |
| Earnings (TTM) | -AU$3.99m |
| Revenue (TTM) | AU$1.65m |
Is NYR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYR income statement (TTM) | |
|---|---|
| Revenue | AU$1.65m |
| Cost of Revenue | AU$2.94m |
| Gross Profit | -AU$1.30m |
| Other Expenses | AU$2.69m |
| Earnings | -AU$3.99m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | -78.58% |
| Net Profit Margin | -241.68% |
| Debt/Equity Ratio | 0% |
How did NYR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/18 16:53 |
| End of Day Share Price | 2025/06/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nyrada Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.